Biostage, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSTG research report →
Companybiostage.com
Biostage, Inc. , a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer.
- CEO
- Junli He
- IPO
- 2013
- Employees
- 7
- HQ
- Holliston, MA, US
Price Chart
Valuation
- Market Cap
- $57.82M
- P/E
- -3.61
- P/S
- 112.39
- P/B
- 267.53
- EV/EBITDA
- -3.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -273.97%
- Op Margin
- -3432.42%
- Net Margin
- -3110.05%
- ROE
- -786.49%
- ROIC
- -2836.60%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,869,000 · 11.16%
- EPS
- $-0.42 · 19.23%
- Op Income
- $-7,619,000
- FCF YoY
- 21.10%
Performance & Tape
- 52W High
- $9.00
- 52W Low
- $3.65
- 50D MA
- $4.75
- 200D MA
- $5.89
- Beta
- -0.97
- Avg Volume
- 972
Get TickerSpark's AI analysis on BSTG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BSTG Coverage
We haven't published any research on BSTG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BSTG Report →